Qiu Shuxing, Zheng Lijun, Qin Chuan, Yin Xing, Ma Jie, Liu Jinjin, Yang Zhaojie, Li Chunwei, Wang Yumei, Wang Mingchen, Qi Yonghua, Huo Yuqi
Xinxiang University of College of Medicine, Xinxiang, PR China.
The Sixth People's Hospital of Zhengzhou, Zhengzhou, PR China.
Microb Pathog. 2020 Feb 26;142:104100. doi: 10.1016/j.micpath.2020.104100.
In this study we generated and characterized a series of monoclonal antibodies (mAbs) against GII.6 norovirus (NoV) virus like particles (VLPs). Mice were immunized with purified GII.6 NoV VLPs and peptide-bovine serum albumin (BSA) conjugates with the peptide sequence (31 aa) derived from the trypsin cleavage region. An indirect enzyme-linked immunosorbent assay was used to identify positive cell clones during cloning and subcloning, and an in vitro VLP-histo-blood group antigens (HBGAs) binding blockade assay was used to identify mAbs with blocking ability. A total of seven mAbs comprising five (1F7, 1F11, 2B6, 2C4, and 2E10) reactive with major capsid proteins (VP1) and two (1E5 and 2B2) reactive with both VP1 proteins and the peptide were identified. mAb 1F7, 1F11, and 2B6 were identified as blocking antibodies. Sandwich ELISA indicated that all these mAbs recognized soluble GII.6 NoV VLPs. Cross-reactivities with GI.7, GII.3, and GII.4 NoV VLPs were observed in indirect and sandwich ELISA. Western blot analysis indicated that all non-blocking mAbs recognized denatured GII.6 VP1 proteins and blocking mAbs only recognized non-denatured proteins. The in vitro VLP-HBGA binding blockade assay indicated that the three blocking antibodies exhibited blocking effects against GII.6 NoV VLPs, but not GI.7, GII.3, and GII.4 NoV VLPs. Epitope mapping and HBGA blocking assay indicated that mAbs targeting the predicted surface-exposed loop region did not have blocking effects, suggesting a possible important role of this region in regulating NoV-HBGA interactions. This is the first report regarding the characterization of mAbs with blocking ability against GII.6 NoV VLPs. These mAbs might be useful in facilitating our understanding of this group of viruses.
在本研究中,我们制备并鉴定了一系列针对GII.6诺如病毒(NoV)病毒样颗粒(VLP)的单克隆抗体(mAb)。用纯化的GII.6 NoV VLP和肽序列(31个氨基酸)来源于胰蛋白酶切割区域的肽 - 牛血清白蛋白(BSA)偶联物免疫小鼠。在克隆和亚克隆过程中,使用间接酶联免疫吸附测定法鉴定阳性细胞克隆,并使用体外VLP - 组织血型抗原(HBGA)结合阻断测定法鉴定具有阻断能力的mAb。共鉴定出七种mAb,其中五种(1F7、1F11、2B6、2C4和2E10)与主要衣壳蛋白(VP1)反应,两种(1E5和2B2)与VP1蛋白和肽均反应。mAb 1F7、1F11和2B6被鉴定为阻断抗体。夹心ELISA表明所有这些mAb都能识别可溶性GII.6 NoV VLP。在间接和夹心ELISA中观察到与GI.7、GII.3和GII.4 NoV VLP的交叉反应性。蛋白质印迹分析表明,所有非阻断性mAb都能识别变性的GII.6 VP1蛋白,而阻断性mAb仅识别非变性蛋白。体外VLP - HBGA结合阻断测定表明,这三种阻断抗体对GII.6 NoV VLP具有阻断作用,但对GI.7、GII.3和GII.4 NoV VLP没有阻断作用。表位作图和HBGA阻断测定表明,靶向预测的表面暴露环区域的mAb没有阻断作用,这表明该区域在调节NoV - HBGA相互作用中可能起重要作用。这是关于具有针对GII.6 NoV VLP阻断能力的mAb表征的首次报告。这些mAb可能有助于我们对这组病毒的理解。